+----------------------+---------+---+---------+--------+--------------+
| ![](media/i          | **R     |   |         | **IN   |              |
| mage1.jpeg){width="0 | ESEARCH |   |         | VESTIG |              |
| .4166666666666667in" | AND     |   |         | ATOR'S |              |
| hei                  | DEVE    |   |         | BIOGRA |              |
| ght="0.2034722222222 | LOPMENT |   |         | PHICAL |              |
| 2222in"}**Department | PR      |   |         | SK     |              |
| of Veterans          | OGRAM** |   |         | ETCH** |              |
| Affairs**            |         |   |         |        |              |
|                      |         |   |         | *      |              |
|                      |         |   |         | **(Not |              |
|                      |         |   |         | to     |              |
|                      |         |   |         | Exceed |              |
|                      |         |   |         | Four   |              |
|                      |         |   |         | Pag    |              |
|                      |         |   |         | es)*** |              |
+----------------------+---------+---+---------+--------+--------------+
| NAME                 |         |   | P       |        |              |
|                      |         |   | OSITION |        |              |
| **Jeffrey A. Jones,  |         |   | TITLE   |        |              |
| Ph.D.**              |         |   |         |        |              |
|                      |         |   | R       |        |              |
|                      |         |   | esearch |        |              |
|                      |         |   | Health  |        |              |
|                      |         |   | Sc      |        |              |
|                      |         |   | ientist |        |              |
|                      |         |   | (VAMC)  |        |              |
|                      |         |   |         |        |              |
|                      |         |   | As      |        |              |
|                      |         |   | sistant |        |              |
|                      |         |   | Pr      |        |              |
|                      |         |   | ofessor |        |              |
|                      |         |   | (MUSC)  |        |              |
+----------------------+---------+---+---------+--------+--------------+
| EDUCATION / TRAINING |         |   |         |        |              |
|                      |         |   |         |        |              |
| (*Begin with         |         |   |         |        |              |
| Baccalaureate or     |         |   |         |        |              |
| other initial        |         |   |         |        |              |
| professional         |         |   |         |        |              |
| education, such as   |         |   |         |        |              |
| nursing, and include |         |   |         |        |              |
| post-doctoral        |         |   |         |        |              |
| training. Do not     |         |   |         |        |              |
| include Honorary     |         |   |         |        |              |
| Degree*.)            |         |   |         |        |              |
+----------------------+---------+---+---------+--------+--------------+
| NAME, LOCATION OF    |         | D |         | YEAR   | FIELD OF     |
| INSTITUTION          |         | E |         | A      | STUDY        |
|                      |         | G |         | WARDED |              |
| University of        |         | R |         |        | Microbiology |
| California, San      |         | E |         | 1987   |              |
| Diego, CA            |         | E |         |        | Biochem. &   |
|                      |         | ( |         | 2003   | Mole. Biol   |
| Medical University   |         | * |         |        |              |
| of South Carolina,   |         | i |         | 200    | Biochem. &   |
| Charleston, SC       |         | f |         | 3-2005 | Mole. Biol   |
|                      |         | a |         |        |              |
| Medical University   |         | p |         |        |              |
| of South Carolina,   |         | p |         |        |              |
| Charleston, SC       |         | l |         |        |              |
|                      |         | i |         |        |              |
|                      |         | c |         |        |              |
|                      |         | a |         |        |              |
|                      |         | b |         |        |              |
|                      |         | l |         |        |              |
|                      |         | e |         |        |              |
|                      |         | * |         |        |              |
|                      |         | ) |         |        |              |
|                      |         |   |         |        |              |
|                      |         | B |         |        |              |
|                      |         | A |         |        |              |
|                      |         |   |         |        |              |
|                      |         | P |         |        |              |
|                      |         | h |         |        |              |
|                      |         | D |         |        |              |
|                      |         |   |         |        |              |
|                      |         | P |         |        |              |
|                      |         | o |         |        |              |
|                      |         | s |         |        |              |
|                      |         | t |         |        |              |
|                      |         | - |         |        |              |
|                      |         | d |         |        |              |
|                      |         | o |         |        |              |
|                      |         | c |         |        |              |
|                      |         | t |         |        |              |
|                      |         | o |         |        |              |
|                      |         | r |         |        |              |
|                      |         | a |         |        |              |
|                      |         | l |         |        |              |
+----------------------+---------+---+---------+--------+--------------+
| **NOTE: The          |         |   |         |        |              |
| Biographical Sketch  |         |   |         |        |              |
| may not exceed four  |         |   |         |        |              |
| pages. Items A and B |         |   |         |        |              |
| (together) may not   |         |   |         |        |              |
| exceed two of the    |         |   |         |        |              |
| four-pages.**        |         |   |         |        |              |
+----------------------+---------+---+---------+--------+--------------+
| A.  Positions and    |         |   |         |        |              |
|     Honors\          |         |   |         |        |              |
|     (List in         |         |   |         |        |              |
|     chronological    |         |   |         |        |              |
|     order previous   |         |   |         |        |              |
|     positions,       |         |   |         |        |              |
|     concluding with  |         |   |         |        |              |
|     your present     |         |   |         |        |              |
|     position. List   |         |   |         |        |              |
|     any honors,      |         |   |         |        |              |
|     professional     |         |   |         |        |              |
|     memberships or   |         |   |         |        |              |
|     present          |         |   |         |        |              |
|     membership on    |         |   |         |        |              |
|     any Federal      |         |   |         |        |              |
|     Government       |         |   |         |        |              |
|     public advisory  |         |   |         |        |              |
|     committee.)      |         |   |         |        |              |
|                      |         |   |         |        |              |
|     Positions and    |         |   |         |        |              |
|     Employment       |         |   |         |        |              |
|                      |         |   |         |        |              |
| 1987-1988 Staff      |         |   |         |        |              |
| Research Associate   |         |   |         |        |              |
| I-1, under *Hudson   |         |   |         |        |              |
| H. Freeze PhD*,      |         |   |         |        |              |
| Cancer Center,       |         |   |         |        |              |
| University of        |         |   |         |        |              |
| California, San      |         |   |         |        |              |
| Diego, La Jolla,     |         |   |         |        |              |
| California           |         |   |         |        |              |
|                      |         |   |         |        |              |
| 1988-1990 Staff      |         |   |         |        |              |
| Research Associate   |         |   |         |        |              |
| I-2, under *Paul A.  |         |   |         |        |              |
| Andrews PhD*, Cancer |         |   |         |        |              |
| Center, University   |         |   |         |        |              |
| of California, San   |         |   |         |        |              |
| Diego, La Jolla,     |         |   |         |        |              |
| California           |         |   |         |        |              |
|                      |         |   |         |        |              |
| 1990- 1994 Staff     |         |   |         |        |              |
| Research Associate   |         |   |         |        |              |
| I-5, under *Stephen  |         |   |         |        |              |
| B. Howell MD*,       |         |   |         |        |              |
| Cancer Center,       |         |   |         |        |              |
| University of        |         |   |         |        |              |
| California, San      |         |   |         |        |              |
| Diego, La Jolla,     |         |   |         |        |              |
| California           |         |   |         |        |              |
|                      |         |   |         |        |              |
| 1994-1998 Research   |         |   |         |        |              |
| Study                |         |   |         |        |              |
| Coordinator/Research |         |   |         |        |              |
| Specialist II for    |         |   |         |        |              |
| *Edward F. McClay    |         |   |         |        |              |
| MD*, Hollings Cancer |         |   |         |        |              |
| Center, The Medical  |         |   |         |        |              |
| University of South  |         |   |         |        |              |
| Carolina,            |         |   |         |        |              |
| Charleston, South    |         |   |         |        |              |
| Carolina             |         |   |         |        |              |
|                      |         |   |         |        |              |
| 1998-2003 Graduate   |         |   |         |        |              |
| Student (PhD),       |         |   |         |        |              |
| Medical Univsersity  |         |   |         |        |              |
| of South Carolina,   |         |   |         |        |              |
| Charleston, South    |         |   |         |        |              |
| Carolina, Mentor:    |         |   |         |        |              |
| *Yusuf A. Hannun,    |         |   |         |        |              |
| MD*                  |         |   |         |        |              |
|                      |         |   |         |        |              |
| 2003-2005            |         |   |         |        |              |
| Post-doctoral        |         |   |         |        |              |
| Fellow, Medical      |         |   |         |        |              |
| University of South  |         |   |         |        |              |
| Carolina,            |         |   |         |        |              |
| Charleston, South    |         |   |         |        |              |
| Carolina,            |         |   |         |        |              |
|                      |         |   |         |        |              |
| Mentor: *Yusuf A.    |         |   |         |        |              |
| Hannun, MD*          |         |   |         |        |              |
|                      |         |   |         |        |              |
| 2005- Assistant      |         |   |         |        |              |
| Professor, Medical   |         |   |         |        |              |
| University of South  |         |   |         |        |              |
| Carolina,            |         |   |         |        |              |
| Charleston, South    |         |   |         |        |              |
| Carolina, Department |         |   |         |        |              |
| of Surgery, Division |         |   |         |        |              |
| of Cardiothoracic    |         |   |         |        |              |
| Surgery Research     |         |   |         |        |              |
|                      |         |   |         |        |              |
| 2008- Research       |         |   |         |        |              |
| Health Scientist,    |         |   |         |        |              |
| Ralph H. Johnson     |         |   |         |        |              |
| Veterans Affairs     |         |   |         |        |              |
| Medical Center,      |         |   |         |        |              |
| Charleston , SC      |         |   |         |        |              |
|                      |         |   |         |        |              |
| **Honors:**          |         |   |         |        |              |
|                      |         |   |         |        |              |
| 2000 Avanti          |         |   |         |        |              |
| Founder's Award,     |         |   |         |        |              |
| Southeast Regional   |         |   |         |        |              |
| Lipid Conference,    |         |   |         |        |              |
| Nov. 1-3, 2000       |         |   |         |        |              |
|                      |         |   |         |        |              |
| 2001 Winner, Poster  |         |   |         |        |              |
| Contest, Hollings    |         |   |         |        |              |
| Cancer Center        |         |   |         |        |              |
| Research Retreat,    |         |   |         |        |              |
| August 31, 2001      |         |   |         |        |              |
|                      |         |   |         |        |              |
| 2001 Second Place,   |         |   |         |        |              |
| Poster Contest, MUSC |         |   |         |        |              |
| Student Research     |         |   |         |        |              |
| Day, November 2,     |         |   |         |        |              |
| 2001                 |         |   |         |        |              |
|                      |         |   |         |        |              |
| 2002 Avanti          |         |   |         |        |              |
| Founder's Award,     |         |   |         |        |              |
| Southeast Regional   |         |   |         |        |              |
| Lipid Conference,    |         |   |         |        |              |
| Nov. 6-8, 2002       |         |   |         |        |              |
|                      |         |   |         |        |              |
| 2002 First Place,    |         |   |         |        |              |
| Poster Contest, MUSC |         |   |         |        |              |
| Student Research     |         |   |         |        |              |
| Day, November 1,     |         |   |         |        |              |
| 2002                 |         |   |         |        |              |
|                      |         |   |         |        |              |
| 2002. Kinard-Gadsen  |         |   |         |        |              |
|       Alumni         |         |   |         |        |              |
|       Research       |         |   |         |        |              |
|       Award, MUSC    |         |   |         |        |              |
|       Student        |         |   |         |        |              |
|       Research Day,  |         |   |         |        |              |
|       November 1,    |         |   |         |        |              |
|       2002           |         |   |         |        |              |
+----------------------+---------+---+---------+--------+--------------+
| B.  Selected         |         |   |         |        |              |
|     peer-reviewed    |         |   |         |        |              |
|     publications (in |         |   |         |        |              |
|     chronological    |         |   |         |        |              |
|     order) (Do not   |         |   |         |        |              |
|     include          |         |   |         |        |              |
|     publications     |         |   |         |        |              |
|     submitted or in  |         |   |         |        |              |
|     prep)            |         |   |         |        |              |
|                      |         |   |         |        |              |
| 1\. Lacoste, C.H.;   |         |   |         |        |              |
| Freeze, H.H.;        |         |   |         |        |              |
| **Jones, J.A.**; and |         |   |         |        |              |
| Kaplan, A.;          |         |   |         |        |              |
| *Characteristics of  |         |   |         |        |              |
| the Sulfation of     |         |   |         |        |              |
| N-Linked             |         |   |         |        |              |
| Oligosaccharides in  |         |   |         |        |              |
| Vesicles from        |         |   |         |        |              |
| Dictyostelium        |         |   |         |        |              |
| discoideum:* *In     |         |   |         |        |              |
| Vitro Sulfation of   |         |   |         |        |              |
| Lysosomal Enzymes*.; |         |   |         |        |              |
| Arch. Biochem.       |         |   |         |        |              |
| Biophys., 273(2):    |         |   |         |        |              |
| 505-515, (1989)      |         |   |         |        |              |
|                      |         |   |         |        |              |
| 2\. Freeze, H.H.;    |         |   |         |        |              |
| Koza-Taylor, P.;     |         |   |         |        |              |
| **Jones, J.A.**; and |         |   |         |        |              |
| Loomis, W.F.;        |         |   |         |        |              |
| *Cell-Free           |         |   |         |        |              |
| N-Glycosylation in   |         |   |         |        |              |
| Dictyostelium        |         |   |         |        |              |
| Discoideum: Analysis |         |   |         |        |              |
| of Wild-Type and     |         |   |         |        |              |
| Mutants Defective in |         |   |         |        |              |
| Lipid-Linked         |         |   |         |        |              |
| Oligosaccharide*.    |         |   |         |        |              |
| Biosynthesis.; J.    |         |   |         |        |              |
| Cell. Biochem., 43:  |         |   |         |        |              |
| 27-42, (1990)        |         |   |         |        |              |
|                      |         |   |         |        |              |
| 3\. Andrews, P.A.;   |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Varki, N.M.; and     |         |   |         |        |              |
| Howell, S.B.; Rapid  |         |   |         |        |              |
| Emergence of         |         |   |         |        |              |
| Acquired             |         |   |         |        |              |
| cis-Diammine         |         |   |         |        |              |
| dichloroplatinum(II) |         |   |         |        |              |
| *Resistance in an In |         |   |         |        |              |
| Vivo Model of Human  |         |   |         |        |              |
| Ovarian Carcinoma*.; |         |   |         |        |              |
| Can. Comm., 2(2):    |         |   |         |        |              |
| 93-100, (1990)       |         |   |         |        |              |
|                      |         |   |         |        |              |
| 4\. Andrews, P.A.;   |         |   |         |        |              |
| and **Jones, J.A.**; |         |   |         |        |              |
| *Characterization of |         |   |         |        |              |
| Binding Proteins     |         |   |         |        |              |
| from Ovarian         |         |   |         |        |              |
| Carcinoma and Kidney |         |   |         |        |              |
| Tubule Cells that    |         |   |         |        |              |
| are Specific for     |         |   |         |        |              |
| Cisplatin Modified   |         |   |         |        |              |
| DNA* \[corrected and |         |   |         |        |              |
| republished article  |         |   |         |        |              |
| originally printed   |         |   |         |        |              |
| in Cancer Commun     |         |   |         |        |              |
| 1991 Jan;            |         |   |         |        |              |
| 3(1):1-10\].; Can,   |         |   |         |        |              |
| Comm., 3: 93-102,    |         |   |         |        |              |
| (1991)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 5\. McClay, E.F.;    |         |   |         |        |              |
| Albright, K.D.;      |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Eastman, A.;         |         |   |         |        |              |
| Christen, R.D.;      |         |   |         |        |              |
| Howell, S.B.;        |         |   |         |        |              |
| *Modulation of       |         |   |         |        |              |
| Cisplatin Resistance |         |   |         |        |              |
| in Human Malignant   |         |   |         |        |              |
| Melanoma Cells*.;    |         |   |         |        |              |
| Cancer Research, 52: |         |   |         |        |              |
| 6790-6796 (1992)     |         |   |         |        |              |
|                      |         |   |         |        |              |
| 6\. McClay, E.F.;    |         |   |         |        |              |
| Albright, K.D.;      |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Christen, R.D.;      |         |   |         |        |              |
| Howell, S.B.;        |         |   |         |        |              |
| *Tamoxifen           |         |   |         |        |              |
| Modulation of        |         |   |         |        |              |
| Cisplatin            |         |   |         |        |              |
| Sensitivity in Human |         |   |         |        |              |
| Malignant Melanoma   |         |   |         |        |              |
| Cells*.; Cancer      |         |   |         |        |              |
| Research 53:         |         |   |         |        |              |
| 1571-1576 (1993)     |         |   |         |        |              |
|                      |         |   |         |        |              |
| 7\. Christen, R.D.;  |         |   |         |        |              |
| Jekunen, A.P.;       |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Thiebaut, F.B.;      |         |   |         |        |              |
| Shalinsky, D.R.; and |         |   |         |        |              |
| Howell, S.B.;        |         |   |         |        |              |
| *Modulation of       |         |   |         |        |              |
| cisplatin            |         |   |         |        |              |
| accumulation in      |         |   |         |        |              |
| human ovarian        |         |   |         |        |              |
| carcinoma cells by   |         |   |         |        |              |
| pharmacological      |         |   |         |        |              |
| alteration of        |         |   |         |        |              |
| microtubules*.; J.   |         |   |         |        |              |
| Clinical Invest.     |         |   |         |        |              |
| 92(1): 431-440       |         |   |         |        |              |
| (1993)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 8\. McClay, E.F.;    |         |   |         |        |              |
| McClay, M.E.;        |         |   |         |        |              |
| Albright, K.D.;      |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Christen, R.D.;      |         |   |         |        |              |
| Alcaraz, J.; and     |         |   |         |        |              |
| Howell, S.B.;        |         |   |         |        |              |
| *Tamoxifen           |         |   |         |        |              |
| Modulation of        |         |   |         |        |              |
| Cisplatin Resistance |         |   |         |        |              |
| in Patients with     |         |   |         |        |              |
| Metastatic           |         |   |         |        |              |
| Melanoma*.; Cancer   |         |   |         |        |              |
| 72(6): 1914-1918     |         |   |         |        |              |
| (1993)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 9\. McClay, E.F.;    |         |   |         |        |              |
| Albright, K.D.;      |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Christen, R.D.;      |         |   |         |        |              |
| Howell, S.B.;        |         |   |         |        |              |
| *Tamoxifen           |         |   |         |        |              |
| Modulation of        |         |   |         |        |              |
| Cisplatin            |         |   |         |        |              |
| Cytotoxicity In      |         |   |         |        |              |
| Human                |         |   |         |        |              |
| Malignancies*.; Int. |         |   |         |        |              |
| J. Cancer 55(6):     |         |   |         |        |              |
| 1018-1022 (1993)     |         |   |         |        |              |
|                      |         |   |         |        |              |
| 10\. Christen, R.D.; |         |   |         |        |              |
| Isonishi, S.;        |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Jekunen, A.P.;       |         |   |         |        |              |
| Thiebaut, F.B.; Hom, |         |   |         |        |              |
| D.K.; Gately, D.P.;  |         |   |         |        |              |
| Los, G.; and Howell, |         |   |         |        |              |
| S.B*.; Signaling and |         |   |         |        |              |
| drug sensitivity*.;  |         |   |         |        |              |
| Cancer & Metastasis  |         |   |         |        |              |
| Reviews 13(2):       |         |   |         |        |              |
| 175-189 (1994)       |         |   |         |        |              |
|                      |         |   |         |        |              |
| 11\. McClay, E.F.;   |         |   |         |        |              |
| Albright, K.D.;      |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Christen, R.D.;      |         |   |         |        |              |
| Howell, S.B.;        |         |   |         |        |              |
| *Tamoxifen delays    |         |   |         |        |              |
| the development of   |         |   |         |        |              |
| resistance to        |         |   |         |        |              |
| cisplatin in human   |         |   |         |        |              |
| melanoma and ovarian |         |   |         |        |              |
| cancer cell lines.*; |         |   |         |        |              |
| Br. J. Cancer 70(3)  |         |   |         |        |              |
| : 449-452 (1994)     |         |   |         |        |              |
|                      |         |   |         |        |              |
| 12\. Gately, D.P.;   |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Christen, R.D.;      |         |   |         |        |              |
| Baton, R.M.; Los,    |         |   |         |        |              |
| G.; and Howell,      |         |   |         |        |              |
| S.B.; *Induction of  |         |   |         |        |              |
| the growth arrest    |         |   |         |        |              |
| and DNA              |         |   |         |        |              |
| damage-inducible     |         |   |         |        |              |
| gene GADD 153 by     |         |   |         |        |              |
| cisplatin in vitro   |         |   |         |        |              |
| and in vivo*.; Br.   |         |   |         |        |              |
| J. Cancer 70(6):     |         |   |         |        |              |
| 1102-1106 (1994)     |         |   |         |        |              |
|                      |         |   |         |        |              |
| 13\. **Jones,        |         |   |         |        |              |
| J.A.**; Gately,      |         |   |         |        |              |
| D.P.; Barton, R.M.;  |         |   |         |        |              |
| Los, G.; Christen,   |         |   |         |        |              |
| R.D.; McClay, E.F.;  |         |   |         |        |              |
| and Howell, S.B.;    |         |   |         |        |              |
| *Induction of gadd   |         |   |         |        |              |
| 153 in human         |         |   |         |        |              |
| melanoma xenografts  |         |   |         |        |              |
| as an indicator of   |         |   |         |        |              |
| genotoxic injury*.;  |         |   |         |        |              |
| Cell. Pharm. 1:      |         |   |         |        |              |
| 233-237 (1994)       |         |   |         |        |              |
|                      |         |   |         |        |              |
| 14\. Kröning, R.;    |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Hom, D.K.; Chuang,   |         |   |         |        |              |
| C.C.; Sanga, R.;     |         |   |         |        |              |
| Los, G.; Howell,     |         |   |         |        |              |
| S.B.; and Christen,  |         |   |         |        |              |
| R.D.; *Enhancement   |         |   |         |        |              |
| of drug sensitivity  |         |   |         |        |              |
| of human             |         |   |         |        |              |
| malignancies by      |         |   |         |        |              |
| epidermal growth     |         |   |         |        |              |
| factor*. Br. J.      |         |   |         |        |              |
| Cancer. 72(3):       |         |   |         |        |              |
| 615-619 (1995)       |         |   |         |        |              |
|                      |         |   |         |        |              |
| 15\. McClay, E.F.;   |         |   |         |        |              |
| Winski, P.J.;        |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Jennerette III, J.;  |         |   |         |        |              |
| and Gattoni-Celli,   |         |   |         |        |              |
| S.;                  |         |   |         |        |              |
| *∆^12                |         |   |         |        |              |
| ^-Prostaglandin-J~2~ |         |   |         |        |              |
| is cytotoxic in      |         |   |         |        |              |
| human malignancies   |         |   |         |        |              |
| an synergizes with   |         |   |         |        |              |
| both cisplatin and   |         |   |         |        |              |
| radiation*. Cancer   |         |   |         |        |              |
| Res. 56: 3866-3869   |         |   |         |        |              |
| (1996)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 16\. McClay, E.F.;   |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Winski, P.J.;        |         |   |         |        |              |
| Albright, K.D.;      |         |   |         |        |              |
| Christen, R.D.; and  |         |   |         |        |              |
| Howell, S.B.;        |         |   |         |        |              |
| *Determinants of     |         |   |         |        |              |
| tamoxifen            |         |   |         |        |              |
| sensitivity control  |         |   |         |        |              |
| the nature of the    |         |   |         |        |              |
| synergistic          |         |   |         |        |              |
| interaction between  |         |   |         |        |              |
| tamoxifen and        |         |   |         |        |              |
| cisplatin*. Cancer   |         |   |         |        |              |
| Res. 56: 3993-3997   |         |   |         |        |              |
| (1996)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 17\. McClay, E.F.;   |         |   |         |        |              |
| McClay, M.E.;        |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Winski, P.J.;        |         |   |         |        |              |
| Christen, R.D.;      |         |   |         |        |              |
| Howell, S.B., Hall,  |         |   |         |        |              |
| P.D.; *A phase I and |         |   |         |        |              |
| pharmacokinetic      |         |   |         |        |              |
| study of high dose   |         |   |         |        |              |
| tamoxifen and weekly |         |   |         |        |              |
| cisplatin in         |         |   |         |        |              |
| patients with        |         |   |         |        |              |
| metastatic           |         |   |         |        |              |
| melanoma*. Cancer    |         |   |         |        |              |
| 79(5): 1037-1043     |         |   |         |        |              |
| (1997)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 18\. **Jones,        |         |   |         |        |              |
| J.A.**; Albright,    |         |   |         |        |              |
| K.D.; Christen,      |         |   |         |        |              |
| R.D.; Howell, S.B.   |         |   |         |        |              |
| and McClay, E.F.;    |         |   |         |        |              |
| *Synergy between     |         |   |         |        |              |
| tamoxifen and        |         |   |         |        |              |
| cisplatin in human   |         |   |         |        |              |
| melanoma cells is    |         |   |         |        |              |
| dependent upon the   |         |   |         |        |              |
| presence of          |         |   |         |        |              |
| antiestrogen binding |         |   |         |        |              |
| sites*. Cancer Res.  |         |   |         |        |              |
| 57:2657-2660 (1997)  |         |   |         |        |              |
|                      |         |   |         |        |              |
| 19. McClay, E.F.;    |         |   |         |        |              |
|     **Jones, J.A.**; |         |   |         |        |              |
|                      |         |   |         |        |              |
|    *Characterization |         |   |         |        |              |
|     of a human       |         |   |         |        |              |
|     melanoma cell    |         |   |         |        |              |
|     line with        |         |   |         |        |              |
|     non-oestrogen    |         |   |         |        |              |
|     receptor         |         |   |         |        |              |
|     dependent        |         |   |         |        |              |
|     tamoxifen        |         |   |         |        |              |
|     resistance*.     |         |   |         |        |              |
|     Melanoma Res.    |         |   |         |        |              |
|     9(6): 531-535    |         |   |         |        |              |
|     (1999)           |         |   |         |        |              |
|                      |         |   |         |        |              |
| 20\. McClay, E.F.;   |         |   |         |        |              |
| McClay, M.E.;        |         |   |         |        |              |
| Monroe, L.; **Jones  |         |   |         |        |              |
| J.A.**; and Winski,  |         |   |         |        |              |
| P.J.; *A phase II    |         |   |         |        |              |
| study of high dose   |         |   |         |        |              |
| tamoxifen and weekly |         |   |         |        |              |
| cisplatin in         |         |   |         |        |              |
| patients with        |         |   |         |        |              |
| metastatic           |         |   |         |        |              |
| melanoma*. Melanoma  |         |   |         |        |              |
| Res. 11(3):309-13    |         |   |         |        |              |
| (2001)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 21\. **Jones, J.A.** |         |   |         |        |              |
| and Hannun, Y.A.;    |         |   |         |        |              |
| *Tight-binding       |         |   |         |        |              |
| inhibition of        |         |   |         |        |              |
| protein              |         |   |         |        |              |
| phosphatase-1 by     |         |   |         |        |              |
| phosphatidic acid:   |         |   |         |        |              |
| Specificity of       |         |   |         |        |              |
| inhibition by the    |         |   |         |        |              |
| phospholipid*. J     |         |   |         |        |              |
| Biol Chem            |         |   |         |        |              |
| 277:15530-15538      |         |   |         |        |              |
| (2002)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 22\. Vaena De        |         |   |         |        |              |
| Avalos, S., **Jones, |         |   |         |        |              |
| J.A.** and Hannun,   |         |   |         |        |              |
| Y.A.; *Ceramide; a   |         |   |         |        |              |
| prototypical         |         |   |         |        |              |
| bioactive lipid at   |         |   |         |        |              |
| the hub of           |         |   |         |        |              |
| sphingolipid         |         |   |         |        |              |
| metabolism*.;        |         |   |         |        |              |
| Bioactive Lipids     |         |   |         |        |              |
| (Chapter 6); A.      |         |   |         |        |              |
| Nicolaou and G.      |         |   |         |        |              |
| Kokotos, eds.        |         |   |         |        |              |
| (Bridgwater, UK, The |         |   |         |        |              |
| Oily Press); (2004)  |         |   |         |        |              |
|                      |         |   |         |        |              |
| 23\. **Jones, J.A.** |         |   |         |        |              |
| and Hannun, Y.A.;    |         |   |         |        |              |
| *Ceramide, cell      |         |   |         |        |              |
| regulation from a    |         |   |         |        |              |
| lipid perspective*.; |         |   |         |        |              |
| Signaling Pathways   |         |   |         |        |              |
| in Liver Diseases    |         |   |         |        |              |
| (Chapter 30);        |         |   |         |        |              |
| Jean-François Dufour |         |   |         |        |              |
| and Pierre-Alain     |         |   |         |        |              |
| Clavien eds.;        |         |   |         |        |              |
| (Heidelberg, DE,     |         |   |         |        |              |
| Springer-Verlag);    |         |   |         |        |              |
| (2005)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 24\. Novgorodov,     |         |   |         |        |              |
| S.A., Szulc, Z.M.,   |         |   |         |        |              |
| Luberto, C.,         |         |   |         |        |              |
| **Jones, J.A.**,     |         |   |         |        |              |
| Bielawski, J.,       |         |   |         |        |              |
| Bielawska, A.,       |         |   |         |        |              |
| Hannun, Y.A., and    |         |   |         |        |              |
| Obeid, L.;           |         |   |         |        |              |
| *Positively charged  |         |   |         |        |              |
| ceramide is a potent |         |   |         |        |              |
| inducer of           |         |   |         |        |              |
| mitochondrial        |         |   |         |        |              |
| permeabilization*.;  |         |   |         |        |              |
| J Biol Chem          |         |   |         |        |              |
| 280:16096-16105      |         |   |         |        |              |
| (2005)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 25\. **Jones,        |         |   |         |        |              |
| J.A.**; Rawles, R.;  |         |   |         |        |              |
| and Hannun, Y.A.;    |         |   |         |        |              |
| *Identification of a |         |   |         |        |              |
| novel phosphatidic   |         |   |         |        |              |
| acid binding domain  |         |   |         |        |              |
| in protein           |         |   |         |        |              |
| phosphatase-1*.      |         |   |         |        |              |
| Biochemistry         |         |   |         |        |              |
| 44(40):13235-13245   |         |   |         |        |              |
| (2005)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 26\. Ikonomidis,     |         |   |         |        |              |
| J.S.; **Jones,       |         |   |         |        |              |
| J.A.**; Barbour,     |         |   |         |        |              |
| J.B.; Stroud, R.E.;  |         |   |         |        |              |
| Clark, L.L.; Kaplan, |         |   |         |        |              |
| B.S.; Zeeshan, A.;   |         |   |         |        |              |
| Bavaria, J.E.;       |         |   |         |        |              |
| Gorman III, J.H.;    |         |   |         |        |              |
| Spinale, F.G.; and   |         |   |         |        |              |
| Gorman, R.C.;        |         |   |         |        |              |
| *Expression of       |         |   |         |        |              |
| matrix               |         |   |         |        |              |
| metalloproteinases   |         |   |         |        |              |
| and endogenous       |         |   |         |        |              |
| inhibitors within    |         |   |         |        |              |
| ascending aneurysms  |         |   |         |        |              |
| of patients with     |         |   |         |        |              |
| Marfan syndrome.*;   |         |   |         |        |              |
| Circulation 114(1    |         |   |         |        |              |
| Suppl):I365-I370     |         |   |         |        |              |
| (2006)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 27\. Snook, C.F.;    |         |   |         |        |              |
| **Jones, J.A.**; and |         |   |         |        |              |
| Hannun, Y.A.;        |         |   |         |        |              |
| *                    |         |   |         |        |              |
| Sphingolipid-binding |         |   |         |        |              |
| Proteins* in Special |         |   |         |        |              |
| Issue: Lipid-Binding |         |   |         |        |              |
| Domains.; Biochemica |         |   |         |        |              |
| Biophysica Acta      |         |   |         |        |              |
| 1761(8):927-4629     |         |   |         |        |              |
| (2006)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 28\. Barbour, J.R.;  |         |   |         |        |              |
| Stroud, R.E.; Lowry, |         |   |         |        |              |
| A.S.; Clark, L.L.;   |         |   |         |        |              |
| Leone, A.M.;         |         |   |         |        |              |
| **Jones, J.A.**;     |         |   |         |        |              |
| Spinale, F.G.; and   |         |   |         |        |              |
| Ikonomidis, J.S.;    |         |   |         |        |              |
| *Temporal Disparity  |         |   |         |        |              |
| in the Induction of  |         |   |         |        |              |
| Matrix               |         |   |         |        |              |
| Metalloproteinases   |         |   |         |        |              |
| and Tissue           |         |   |         |        |              |
| Inhibitors of        |         |   |         |        |              |
| Metalloproteinases   |         |   |         |        |              |
| Following Thoracic   |         |   |         |        |              |
| Aortic Aneurysm      |         |   |         |        |              |
| Formation*. J Thorac |         |   |         |        |              |
| Cardiovasc Surg      |         |   |         |        |              |
| 132:788-795 (2006)   |         |   |         |        |              |
|                      |         |   |         |        |              |
| 29\. **Jones,        |         |   |         |        |              |
| J.A.**; Barbour,     |         |   |         |        |              |
| J.R.; Lowry, A.S.;   |         |   |         |        |              |
| Bouges, S.; Beck,    |         |   |         |        |              |
| C.; McClister, D.M.; |         |   |         |        |              |
| Mukherjee, R.; and   |         |   |         |        |              |
| Ikonomidis, J.S.;    |         |   |         |        |              |
| *Spatiotemporal      |         |   |         |        |              |
| Expression and       |         |   |         |        |              |
| Localization of      |         |   |         |        |              |
| Matrix               |         |   |         |        |              |
| Metalloproteinase-9  |         |   |         |        |              |
| in a Murine Thoracic |         |   |         |        |              |
| Aortic Aneurysm      |         |   |         |        |              |
| Model.*; J Vasc Surg |         |   |         |        |              |
| 44:1314-1321 (2006)  |         |   |         |        |              |
| **PMCID:**           |         |   |         |        |              |
| *PMC1761919*         |         |   |         |        |              |
|                      |         |   |         |        |              |
| 30\. Ikonomidis JS,  |         |   |         |        |              |
| **Jones JA**,        |         |   |         |        |              |
| Barbour JR, Stroud   |         |   |         |        |              |
| RE, Clark LL, Kaplan |         |   |         |        |              |
| BS, Zeeshan A,       |         |   |         |        |              |
| Bavaria JE, Gorman   |         |   |         |        |              |
| JH 3rd, Spinale FG,  |         |   |         |        |              |
| Gorman RC.;          |         |   |         |        |              |
| *Expression of       |         |   |         |        |              |
| matrix               |         |   |         |        |              |
| metalloproteinases   |         |   |         |        |              |
| and endogenous       |         |   |         |        |              |
| inhibitors within    |         |   |         |        |              |
| ascending aortic     |         |   |         |        |              |
| aneurysms of         |         |   |         |        |              |
| patients with        |         |   |         |        |              |
| bicuspid or          |         |   |         |        |              |
| tricuspid aortic     |         |   |         |        |              |
| valves*. J Thorac    |         |   |         |        |              |
| Cardiovasc Surg.     |         |   |         |        |              |
| 133(4):1028-36       |         |   |         |        |              |
| (2007)               |         |   |         |        |              |
|                      |         |   |         |        |              |
| 31\. **Jones J.A.**, |         |   |         |        |              |
| Stroud R.E., Kaplan  |         |   |         |        |              |
| B.S., Leone A.M.,    |         |   |         |        |              |
| Bavaria J.E., Gorman |         |   |         |        |              |
| J.H. III, Gorman     |         |   |         |        |              |
| R.C., and Ikonomidis |         |   |         |        |              |
| J.S.; *Differential  |         |   |         |        |              |
| Protein Kinase C     |         |   |         |        |              |
| Isoform Abundance in |         |   |         |        |              |
| Ascending Aortic     |         |   |         |        |              |
| Aneurysms from       |         |   |         |        |              |
| Patients with        |         |   |         |        |              |
| Bicuspid versus      |         |   |         |        |              |
| Tricuspid Aortic     |         |   |         |        |              |
| Valves*. Circulation |         |   |         |        |              |
| 116(suppl            |         |   |         |        |              |
| I):I144-I149 (2007)  |         |   |         |        |              |
|                      |         |   |         |        |              |
| 32\. Marchesini, N.; |         |   |         |        |              |
| **Jones, J.A.**; and |         |   |         |        |              |
| Hannun, Y.A.;        |         |   |         |        |              |
| *Confluence induced  |         |   |         |        |              |
| threonine41/serine45 |         |   |         |        |              |
| phospho-β-catenin    |         |   |         |        |              |
| dephosphorylation    |         |   |         |        |              |
| via                  |         |   |         |        |              |
| ceramide-mediated    |         |   |         |        |              |
| activation of        |         |   |         |        |              |
| PP1cγ*. Biochim      |         |   |         |        |              |
| Biophys Acta         |         |   |         |        |              |
| 1771(12):1418-28     |         |   |         |        |              |
| (2007) **PMCID:**    |         |   |         |        |              |
| *PMC2277505*         |         |   |         |        |              |
|                      |         |   |         |        |              |
| 33\. **Jones J.A**.; |         |   |         |        |              |
| Barbour J.R.; Stroud |         |   |         |        |              |
| R.E.; Bouges S.;     |         |   |         |        |              |
| Stephens S.L.;       |         |   |         |        |              |
| Spinale F.G.; and    |         |   |         |        |              |
| Ikonomidis J.S.;     |         |   |         |        |              |
| *Altered             |         |   |         |        |              |
| Transforming Growth  |         |   |         |        |              |
| Factor-beta          |         |   |         |        |              |
| Signaling in a       |         |   |         |        |              |
| Murine Model of      |         |   |         |        |              |
| Thoracic Aortic      |         |   |         |        |              |
| Aneurysm.*; J Vasc   |         |   |         |        |              |
| Res 45:457-68 (2008) |         |   |         |        |              |
| **PMCID:**           |         |   |         |        |              |
| *PMC2574785*         |         |   |         |        |              |
|                      |         |   |         |        |              |
| 34\. **Jones J.A.**, |         |   |         |        |              |
| Spinale F.G., and    |         |   |         |        |              |
| Ikonomidis J.S.;     |         |   |         |        |              |
| *Transforming Growth |         |   |         |        |              |
| Factor-beta          |         |   |         |        |              |
| signaling in         |         |   |         |        |              |
| thoracic aortic      |         |   |         |        |              |
| aneurysm             |         |   |         |        |              |
| development: a       |         |   |         |        |              |
| paradox in           |         |   |         |        |              |
| pathogenesis*.       |         |   |         |        |              |
| (Review); J Vasc Res |         |   |         |        |              |
| 46:119-137 (2008)    |         |   |         |        |              |
| **PMCID:** *Waiting  |         |   |         |        |              |
| for Release*         |         |   |         |        |              |
|                      |         |   |         |        |              |
| 35\. Ruddy J.M.,     |         |   |         |        |              |
| **Jones J.A.**,      |         |   |         |        |              |
| Spinale F.G., and    |         |   |         |        |              |
| Ikonomidis J.S.;     |         |   |         |        |              |
| *Regional            |         |   |         |        |              |
| heterogeneity within |         |   |         |        |              |
| the aorta: Relevance |         |   |         |        |              |
| to aneurysm          |         |   |         |        |              |
| disease.* (Review);  |         |   |         |        |              |
| J Thorac Cardiovasc  |         |   |         |        |              |
| Surg 136:1123-1130   |         |   |         |        |              |
| (2008) **PMCID:**    |         |   |         |        |              |
| *In Process*         |         |   |         |        |              |
+----------------------+---------+---+---------+--------+--------------+
| C.  Research         |         |   |         |        |              |
|     Support\         |         |   |         |        |              |
|     List selected    |         |   |         |        |              |
|     ongoing or       |         |   |         |        |              |
|     completed        |         |   |         |        |              |
|     (during the last |         |   |         |        |              |
|     three years)     |         |   |         |        |              |
|     research         |         |   |         |        |              |
|     projects         |         |   |         |        |              |
|     (federal and     |         |   |         |        |              |
|     non-federal      |         |   |         |        |              |
|     support). Begin  |         |   |         |        |              |
|     with the         |         |   |         |        |              |
|     projects that    |         |   |         |        |              |
|     are most         |         |   |         |        |              |
|     relevant to the  |         |   |         |        |              |
|     research         |         |   |         |        |              |
|     proposed in this |         |   |         |        |              |
|     application.     |         |   |         |        |              |
|     Briefly indicate |         |   |         |        |              |
|     the overall      |         |   |         |        |              |
|     goals of the     |         |   |         |        |              |
|     projects and     |         |   |         |        |              |
|     your role (e.g.  |         |   |         |        |              |
|     PI,              |         |   |         |        |              |
|     Co-Investigator, |         |   |         |        |              |
|     Consultant) in   |         |   |         |        |              |
|     the research     |         |   |         |        |              |
|     project. Do not  |         |   |         |        |              |
|     list award       |         |   |         |        |              |
|     amounts or       |         |   |         |        |              |
|     percent effort   |         |   |         |        |              |
|     in projects.     |         |   |         |        |              |
|                      |         |   |         |        |              |
| **[Ongoing Research  |         |   |         |        |              |
| Su                   |         |   |         |        |              |
| pport]{.underline}** |         |   |         |        |              |
|                      |         |   |         |        |              |
| **Department of      |         |   |         |        |              |
| Veterans Affairs**   |         |   |         |        |              |
| (Career Development  |         |   |         |        |              |
| Award, CDA-2)        |         |   |         |        |              |
|                      |         |   |         |        |              |
| 01.06.2008 --        |         |   |         |        |              |
| 12.31.2011           |         |   |         |        |              |
|                      |         |   |         |        |              |
| *Role*: Principal    |         |   |         |        |              |
| Investigator         |         |   |         |        |              |
|                      |         |   |         |        |              |
| [Intracellular       |         |   |         |        |              |
| Signaling in         |         |   |         |        |              |
| Thoracic Aortic      |         |   |         |        |              |
| Aneurysm             |         |   |         |        |              |
| Deve                 |         |   |         |        |              |
| lopment]{.underline} |         |   |         |        |              |
|                      |         |   |         |        |              |
| The overall goal of  |         |   |         |        |              |
| this project is to   |         |   |         |        |              |
| establish a role for |         |   |         |        |              |
| specific protein     |         |   |         |        |              |
| kinase C (PKC)       |         |   |         |        |              |
| isoform signaling    |         |   |         |        |              |
| with respect to      |         |   |         |        |              |
| thoracic aortic      |         |   |         |        |              |
| aneurysm             |         |   |         |        |              |
| development,         |         |   |         |        |              |
| carefully            |         |   |         |        |              |
| delineating the      |         |   |         |        |              |
| PKC-mediated shift   |         |   |         |        |              |
| in balance between   |         |   |         |        |              |
| extracellular matrix |         |   |         |        |              |
| deposition and       |         |   |         |        |              |
| degradation toward   |         |   |         |        |              |
| enhanced             |         |   |         |        |              |
| proteolysis. This    |         |   |         |        |              |
| line of              |         |   |         |        |              |
| investigation        |         |   |         |        |              |
| represents a novel   |         |   |         |        |              |
| paradigm in which    |         |   |         |        |              |
| the loss of a        |         |   |         |        |              |
| specific upstream    |         |   |         |        |              |
| intracellular        |         |   |         |        |              |
| signaling mediator   |         |   |         |        |              |
| may serve to         |         |   |         |        |              |
| exacerbate           |         |   |         |        |              |
| pathological         |         |   |         |        |              |
| vascular remodeling  |         |   |         |        |              |
| and aneurysmal       |         |   |         |        |              |
| growth.              |         |   |         |        |              |
|                      |         |   |         |        |              |
| **NIH R21            |         |   |         |        |              |
| HL089170-01** (PI    |         |   |         |        |              |
| Ikonomidis)          |         |   |         |        |              |
|                      |         |   |         |        |              |
| 05.01.2008 --        |         |   |         |        |              |
| 04.30.2010           |         |   |         |        |              |
|                      |         |   |         |        |              |
| *Role*:              |         |   |         |        |              |
| Co-Investigator      |         |   |         |        |              |
|                      |         |   |         |        |              |
| [Intracellular       |         |   |         |        |              |
| Signaling in         |         |   |         |        |              |
| Thoracic Aortic      |         |   |         |        |              |
| An                   |         |   |         |        |              |
| eurysms]{.underline} |         |   |         |        |              |
|                      |         |   |         |        |              |
| This project will    |         |   |         |        |              |
| interrogate a large  |         |   |         |        |              |
| bank of human tissue |         |   |         |        |              |
| specimens from       |         |   |         |        |              |
| patients with        |         |   |         |        |              |
| ascending thoracic   |         |   |         |        |              |
| aortic aneurysms in  |         |   |         |        |              |
| order to establish   |         |   |         |        |              |
| the role of specific |         |   |         |        |              |
| signaling pathways   |         |   |         |        |              |
| (TGF-, TNF-) and     |         |   |         |        |              |
| signaling            |         |   |         |        |              |
| intermediates (PKC,  |         |   |         |        |              |
| NFB) in the          |         |   |         |        |              |
| induction of         |         |   |         |        |              |
| aberrant vascular    |         |   |         |        |              |
| remodeling and       |         |   |         |        |              |
| development of ATAA. |         |   |         |        |              |
| This project will    |         |   |         |        |              |
| advance our          |         |   |         |        |              |
| understanding of the |         |   |         |        |              |
| signaling events     |         |   |         |        |              |
| that contribute to   |         |   |         |        |              |
| the formation and    |         |   |         |        |              |
| progression of ATAA  |         |   |         |        |              |
| and could result in  |         |   |         |        |              |
| novel diagnostics or |         |   |         |        |              |
| therapeutic          |         |   |         |        |              |
| strategies for the   |         |   |         |        |              |
| treatment of         |         |   |         |        |              |
| aneurysm disease.    |         |   |         |        |              |
|                      |         |   |         |        |              |
| [Completed Research  |         |   |         |        |              |
| Support]{.underline} |         |   |         |        |              |
|                      |         |   |         |        |              |
| AHA 0110155U Jones   |         |   |         |        |              |
| (PI)                 |         |   |         |        |              |
| 0                    |         |   |         |        |              |
| 7/01/2001-06/30/2003 |         |   |         |        |              |
|                      |         |   |         |        |              |
| American Heart       |         |   |         |        |              |
| Association          |         |   |         |        |              |
|                      |         |   |         |        |              |
| Pre-doctoral         |         |   |         |        |              |
| Research Fellowship, |         |   |         |        |              |
| Mid-Atlantic         |         |   |         |        |              |
| Affiliate            |         |   |         |        |              |
|                      |         |   |         |        |              |
| The goal of this     |         |   |         |        |              |
| project was to       |         |   |         |        |              |
| define the           |         |   |         |        |              |
| biochemical          |         |   |         |        |              |
| characteristics of   |         |   |         |        |              |
| the direct           |         |   |         |        |              |
| interaction between  |         |   |         |        |              |
| phosphatidic acid    |         |   |         |        |              |
| and protein          |         |   |         |        |              |
| phosphatase-1, and   |         |   |         |        |              |
| characterize the     |         |   |         |        |              |
| physical             |         |   |         |        |              |
| interaction,         |         |   |         |        |              |
| including the        |         |   |         |        |              |
| binding domain,      |         |   |         |        |              |
| between this lipid   |         |   |         |        |              |
| and protein.         |         |   |         |        |              |
|                      |         |   |         |        |              |
| Role: PI             |         |   |         |        |              |
+----------------------+---------+---+---------+--------+--------------+
| D.  Time and Effort  |         |   |         |        |              |
|     Statement\       |         |   |         |        |              |
|     Indicate         |         |   |         |        |              |
|     percentage of    |         |   |         |        |              |
|     time spent on    |         |   |         |        |              |
|     research,        |         |   |         |        |              |
|     clinical,        |         |   |         |        |              |
|                      |         |   |         |        |              |
|  teaching/mentoring, |         |   |         |        |              |
|     and              |         |   |         |        |              |
|     administration.  |         |   |         |        |              |
|     List persons     |         |   |         |        |              |
|     mentored in last |         |   |         |        |              |
|     3 years and type |         |   |         |        |              |
|     of mentoring     |         |   |         |        |              |
|     awards.          |         |   |         |        |              |
|                      |         |   |         |        |              |
| **% Effort:          |         |   |         |        |              |
| Researc              |         |   |         |        |              |
| h=[90]{.underline}%; |         |   |         |        |              |
| Clinic               |         |   |         |        |              |
| al=[0]{.underline}%; |         |   |         |        |              |
| Teaching/Mentori     |         |   |         |        |              |
| ng=[5]{.underline}%; |         |   |         |        |              |
| Administratio        |         |   |         |        |              |
| n=[5]{.underline}%** |         |   |         |        |              |
|                      |         |   |         |        |              |
| The applicant has a  |         |   |         |        |              |
| Medical University   |         |   |         |        |              |
| appointment and is   |         |   |         |        |              |
| not currently        |         |   |         |        |              |
| employed by the VA.  |         |   |         |        |              |
| A statement of       |         |   |         |        |              |
| employment           |         |   |         |        |              |
| eligibility signed   |         |   |         |        |              |
| by the Acting Chief, |         |   |         |        |              |
| VAMC Human Resources |         |   |         |        |              |
| Management Service   |         |   |         |        |              |
| is attached. A       |         |   |         |        |              |
| 5/8ths VA            |         |   |         |        |              |
| appointment is       |         |   |         |        |              |
| requested, of which  |         |   |         |        |              |
| 100% effort will be  |         |   |         |        |              |
| dedicated to this    |         |   |         |        |              |
| proposal.            |         |   |         |        |              |
+----------------------+---------+---+---------+--------+--------------+
| E.  Significant Life |         |   |         |        |              |
|     Events           |         |   |         |        |              |
|     (OPTIONAL)\      |         |   |         |        |              |
|     List any         |         |   |         |        |              |
|     significant life |         |   |         |        |              |
|     events that have |         |   |         |        |              |
|     interrupted the  |         |   |         |        |              |
|     PI's research    |         |   |         |        |              |
|     activities for a |         |   |         |        |              |
|     significant      |         |   |         |        |              |
|     period of time.  |         |   |         |        |              |
|                      |         |   |         |        |              |
| None                 |         |   |         |        |              |
+----------------------+---------+---+---------+--------+--------------+